Cantor Fitzgerald Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its price objective raised by research analysts at Cantor Fitzgerald from $120.00 to $145.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 1.64% from the company’s current price.

Several other analysts have also recently weighed in on the company. Guggenheim boosted their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Jefferies Financial Group raised their price objective on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. Rothschild & Co Redburn boosted their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Finally, HSBC upped their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $151.32.

Merck & Co., Inc. Stock Up 0.5%

Shares of MRK opened at $142.66 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The stock has a market capitalization of $351.96 billion, a price-to-earnings ratio of 114.12, a PEG ratio of 6.18 and a beta of 0.21. The stock has a fifty day moving average of $143.34 and a 200-day moving average of $127.96.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the company posted $2.13 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Deluca sold 11,699 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vann Equity Management LLC lifted its position in shares of Merck & Co., Inc. by 87.4% during the third quarter. Vann Equity Management LLC now owns 5,215 shares of the company’s stock valued at $758,000 after purchasing an additional 2,432 shares in the last quarter. Retirement Wealth Solutions LLC raised its stake in shares of Merck & Co., Inc. by 22.0% in the third quarter. Retirement Wealth Solutions LLC now owns 703 shares of the company’s stock valued at $102,000 after buying an additional 127 shares during the period. Cooper Financial Group lifted its holdings in Merck & Co., Inc. by 2.4% during the third quarter. Cooper Financial Group now owns 8,281 shares of the company’s stock valued at $1,203,000 after purchasing an additional 192 shares during the last quarter. Canandaigua National Trust Co of Florida bought a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $1,673,000. Finally, Baring Financial LLC purchased a new position in shares of Merck & Co., Inc. in the third quarter valued at $219,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.